Fate Therapeutics, Inc. Stock price

Equities

FATE

US31189P1021

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
7.34 USD +7.00% Intraday chart for Fate Therapeutics, Inc. -1.21% +96.26%
Sales 2024 * 4.73M Sales 2025 * 4.85M Capitalization 835M
Net income 2024 * -195M Net income 2025 * -211M EV / Sales 2024 * 134 x
Net cash position 2024 * 202M Net cash position 2025 * 124M EV / Sales 2025 * 147 x
P/E ratio 2024 *
-4.15 x
P/E ratio 2025 *
-4.45 x
Employees 181
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.53%
More Fundamentals * Assessed data
Dynamic Chart
Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC CI
Fate Therapeutics Prices $100 Million Offering, Private Placement MT
Fate Therapeutics, Inc. announced that it expects to receive $19.996366 million in funding from Redmile Group, LLC CI
Fate Therapeutics, Inc.(NasdaqGM:FATE) added to S&P Biotechnology Select Industry Index CI
Transcript : Fate Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 11:15 AM
Morgan Stanley Raises Fate Therapeutics Price Target to $7 From $3, Maintains Equalweight Rating MT
BMO Capital Adjusts Price Target on Fate Therapeutics to $7 From $6, Maintains Market Perform Rating MT
Barclays Adjusts Price Target on Fate Therapeutics to $10 From $6, Maintains Overweight Rating MT
Wedbush Raises Fate Therapeutics' Price Target to $7 From $3, Keeps Neutral Rating MT
Transcript : Fate Therapeutics, Inc., Q4 2023 Earnings Call, Feb 26, 2024
Fate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (FATE) FATE THERAPEUTICS Posts Q4 Revenue $1.7M, vs. Street Est of $1.5M MT
Fate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Fate Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors CI
Fate Therapeutics, Inc.(NasdaqGM:FATE) dropped from NASDAQ Biotechnology Index CI
More news
1 day+7.00%
1 week-1.21%
Current month+3.53%
1 month-1.61%
3 months+100.55%
6 months+249.52%
Current year+96.26%
More quotes
1 week
6.54
Extreme 6.54
7.59
1 month
6.54
Extreme 6.54
8.83
Current year
3.46
Extreme 3.455
8.83
1 year
1.63
Extreme 1.63
8.83
3 years
1.63
Extreme 1.63
97.43
5 years
1.63
Extreme 1.63
121.16
10 years
1.46
Extreme 1.46
121.16
More quotes
Managers TitleAgeSince
Founder 53 07-04-26
Director of Finance/CFO 49 20-08-16
Chairman 75 11-10-31
Members of the board TitleAgeSince
Director/Board Member 69 14-03-16
Director/Board Member 61 20-04-30
Director/Board Member 57 13-07-31
More insiders
Date Price Change Volume
24-03-27 7.34 +7.00% 2,110,595
24-03-26 6.86 -0.15% 2,942,788
24-03-25 6.87 +3.93% 1,986,574
24-03-22 6.61 -11.04% 1,997,087
24-03-21 7.43 0.00% 1,991,588

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of programmed cellular immunotherapies for patients with cancer and autoimmune disorders. It uses human induced pluripotent stem cells (iPSCs) generated from its iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The Company is advancing a pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted natural killer (NK) and T-cell product candidates. The Company's product pipeline includes FT576, FT819, FT825 and FT522. Its FT576, is an iPSC-derived, B-cell maturation antigen (BCMA)-targeted CAR NK cell product candidate for the treatment of multiple myeloma. Its FT819, is an iPSC-derived CAR T-cell therapy candidate, which is in Phase I study for the treatment of adult patients with relapsed / refractory B-cell malignancies, including B-cell lymphoma and chronic lymphocytic leukemia.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
7.34 USD
Average target price
7.533 USD
Spread / Average Target
+2.63%
Consensus
  1. Stock
  2. Equities
  3. Stock Fate Therapeutics, Inc. - Nasdaq